Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Jul 09, 2018

SOUTH PLAINFIELD, N.J. , July 9, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced the presentation of data from the Translarna (ataluren) Phase II Study 030 demonstrating that the safety and pharmacokinetic profile of Translarna in children from two to five years with

Additional Formats
Jun 16, 2018

- risdiplam (RG7916) is well tolerated at all dose levels with no drug-related safety findings - SOUTH PLAINFIELD, N.J. , June 16, 2018 /PRNewswire/ --   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of updated interim clinical data from Part 1 of the FIREFISH study

Additional Formats
Jun 08, 2018

SOUTH PLAINFIELD, N.J. , June 8, 2018 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on June 7 , 2018 it approved non-statutory stock options to purchase an aggregate of 134,450 shares of its common stock to 18 new employees and a restricted stock unit for 3,000 shares

Additional Formats
Jun 01, 2018

- European Commission ratification anticipated in coming months - - Approval of the Translarna annual re-assessment also recommended by CHMP - SOUTH PLAINFIELD, N.J. , June 1, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Committee for Medicinal Products for

Additional Formats
May 09, 2018

SOUTH PLAINFIELD, N.J. , May 9, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the first quarter ending March 31, 2018 . "Over the past twenty years it has been our mission to bring clinically differentiated

Additional Formats
May 01, 2018

SOUTH PLAINFIELD, N.J. , May 1, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter 2018 financial results and provide an update on the company's business and outlook on Wednesday, May 9, 2018 at

Additional Formats
Apr 30, 2018

SOUTH PLAINFIELD, N.J. , April 30, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Bank of America Merrill Lynch 2018 Health Care Conference , on Tuesday, May 15th at 2:20 p.m.

Additional Formats
Apr 27, 2018

SOUTH PLAINFIELD, N.J. , April 27, 2018 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on April 24 , 2018 it approved non-statutory stock options to purchase an aggregate of 172,150 shares of its common stock to 25 new employees and a restricted stock unit for 4,000

Additional Formats
Apr 24, 2018

SOUTH PLAINFIELD, N.J. , April. 24, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of preliminary data from Part 1, the dose finding portion, of the ongoing FIREFISH clinical trial. The open-label trial is evaluating RG7916, an oral survival motor

Additional Formats
Apr 12, 2018

SOUTH PLAINFIELD, N.J. , April 12, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that the underwriters of its previously announced public offering of 4,000,000 shares of its common stock, which closed on April 3, 2018 , have exercised in full their option to purchase

Additional Formats